Twenty-eight of 42 participants in a prospective 2-year clinical trial of OctLAR ( 40 mg monthly ) consisting of double-blind , randomized ( year 1 ) and open-label treatment ( year 2 ) phases reenrolled in a 2-year open-label extension ( OLE ) study after being off OctLAR a mean of 8.3 months ( original study : July 1 , 2007 , through June 30 , 2013 ) .